Cargando…
Loading, please waitCargando…
Loading, please waitCondition — Metabolic
Type 2 diabetes (ICD-10 E11) is a chronic, multifactorial metabolic disease. At Regeneris Therapy we combine the 2026 evidence on mesenchymal stem cells with your endocrine treatment to improve glycemic control, reduce inflammation and, in selected patients, decrease medication requirements under medical supervision.
Type 2 diabetes mellitus (T2D, ICD-10 E11) is a chronic metabolic disease characterized by sustained hyperglycemia secondary to a combination of insulin resistance in muscle, liver and adipose tissue, together with progressive pancreatic beta-cell dysfunction. It affects roughly 14 % of the adult population in Mexico according to ENSANUT surveys, and represents the leading cause of mortality and acquired blindness in the country. It is not an older-adult disease: it is being diagnosed earlier and earlier, even in adolescents with obesity.
For decades it was described as a progressive, one-way disease: insulin resistance worsens, beta cells exhaust themselves, medication doses go up and complications accumulate. The biology we understand in 2026 is more dynamic. Beta cells are not always destroyed in T2D; many are exhausted, dedifferentiated or functionally silenced by chronic inflammation and metabolic stress. Insulin resistance is also not a fixed defect: it is a state shaped by inflammatory signaling in adipose tissue, liver and skeletal muscle.
This biological revision is the reason mesenchymal stem cells (MSCs) have entered the diabetes conversation at all. If part of the disease is driven by chronic low-grade inflammation and miscalibrated cellular signaling, then a cellular therapy with immunomodulatory and anti-inflammatory properties becomes scientifically interesting — not as a cure, but as a possible adjunct. At Regeneris Therapy we talk about **stem cells for type 2 diabetes** with the same honesty we apply to every regenerative tool: what the evidence supports, what it does not, and who is a reasonable candidate.
We operate in Cancún under a COFEPRIS aviso de funcionamiento, work with Mexican laboratories certified for cellular processing and our medical team, led by Dr. Claudia Labastida, evaluates each case individually. We coordinate with your endocrinologist or internist of record. We do not replace their treatment: we complement it when there is a clear clinical argument. If you are not a candidate, we will say so with the same clarity.
Type 2 diabetes does not have a single cause. It is the result of a complex interaction between genetics, environment and lifestyle. The hereditary predisposition is clear: having a first-degree relative with T2D doubles or triples the risk, and more than 100 genetic variants have been identified. But genetics alone do not produce the disease: the environment is the trigger.
The principal metabolic driver is insulin resistance. Under normal conditions, insulin opens receptors on muscle, liver and adipose cells so glucose can enter and be used for energy. When there is excess visceral adipose tissue, sedentary behavior, an ultra-processed diet and disturbed sleep patterns, intracellular inflammatory pathways (TNF-α, IL-6, NF-κB) interfere with that signaling. Glucose does not enter efficiently, blood levels rise, and the pancreas responds by producing more insulin — until beta cells exhaust themselves.
That chronic hyperinsulinemia is, paradoxically, part of the problem. It promotes more visceral fat accumulation, dyslipidemia (high triglycerides, low HDL), hypertension and a systemic pro-inflammatory state. This is known as metabolic syndrome, and it precedes the diagnosis of diabetes by years or even decades. HbA1c above 6.5 %, or fasting glucose greater than 126 mg/dL on two occasions, are the diagnostic cutoffs according to the ADA.
There are modifiable and non-modifiable risk factors. Non-modifiable ones include age over 45, family history, ethnicity (higher risk in Hispanic, African American, Asian and Indigenous populations), prior gestational diabetes and polycystic ovary syndrome. Modifiable factors — where most of the therapeutic leverage lives — include abdominal obesity (waist circumference greater than 90 cm in men and 80 cm in women), sedentary behavior, a diet high in simple sugars and refined flours, insufficient or fragmented sleep, chronic stress, smoking and prolonged vitamin D deficiency.
Chronic low-grade inflammation is the common thread. In type 2 diabetes, elevated levels of high-sensitivity C-reactive protein (hs-CRP), IL-6, TNF-α and other inflammatory markers are documented. That inflammation does not just worsen insulin resistance: it contributes to the endothelial damage that explains long-term complications — retinopathy, nephropathy, neuropathy and cardiovascular disease, which remains the leading cause of death in patients with T2D.
The cornerstone of type 2 diabetes treatment is and will remain the combination of lifestyle change (nutrition, activity, sleep) with guideline-based medications: metformin as first line, GLP-1 agonists (semaglutide, tirzepatide), SGLT2 inhibitors and, when required, insulin. No regenerative therapy replaces them. What we can offer at Regeneris Therapy are adjunct protocols with reasonable evidence that, in selected patients, can complement that treatment.
Mesenchymal stem cells (MSCs) are the most studied regenerative component in T2D. The 2026 evidence — phase I and II trials published in journals such as *Stem Cells Translational Medicine*, *Diabetes Care* and *Cell Transplantation* — documents HbA1c reductions in the range of 0.5 to 1.5 percentage points, decreased insulin requirements in insulin-dependent patients, improved HOMA-IR and reduced inflammatory markers. Responders tend to be patients with relatively short disease duration (less than 10–15 years), measurable C-peptide (preserved beta-cell reserve) and absence of advanced active complications. Large multi-center phase III trials that would move MSCs from investigational adjunct to standard of care have not yet reported.
The dominant mechanism is not differentiation into new beta cells — that early hypothesis did not hold up. The current model is that MSCs act as immunometabolic modulators: they release cytokines, growth factors and extracellular vesicles that calm inflammation, improve peripheral insulin sensitivity and give the patient's remaining beta cells a better environment in which to function. After intravenous infusion, MSCs temporarily home to lung, liver and spleen, exerting systemic effects from there.
We pair MSCs with targeted IV micronutrient therapy when documented deficiencies exist (vitamin D, B12, magnesium, chromium, alpha-lipoic acid) or when inflammatory and oxidative-stress markers are elevated. NAD+, glutathione and vitamin C at adapted doses are useful tools to support mitochondrial function and antioxidant status — without replacing pharmacologic treatment. When appropriate, we integrate metabolic peptide therapy under medical supervision and a structured nutrition and activity plan.
Before applying any regenerative protocol, we run a complete metabolic evaluation: HbA1c, fasting glucose, baseline insulin, HOMA-IR, C-peptide, full lipid panel, kidney and liver function, inflammatory markers (hs-CRP), microalbuminuria, thyroid panel and, as appropriate, referrals to ophthalmology and cardiology. If we find contraindications or your clinical picture does not support treatment, we explain that frankly and orient you toward the options that do make sense for your case.
Linked protocols
MSC protocols using Wharton's jelly cells processed in a COFEPRIS-certified laboratory, as a metabolic adjunct.
NAD+, glutathione, B-complex and antioxidant protocols to support mitochondria, cellular function and inflammatory status.
Evaluation with Dr. Claudia Labastida and the Regeneris team to design your individualized protocol.
Explore regenerative medicine
See the full landscape of treatments we offer in Cancún and the science behind each one.
The prognosis of type 2 diabetes has improved meaningfully over the last decade, especially since the integration of GLP-1 agonists and SGLT2 inhibitors into management guidelines. With sustained glycemic control (HbA1c below 7 %), blood-pressure control, optimized lipids and adjusted lifestyle, most patients can significantly delay or avoid microvascular complications (retinopathy, nephropathy, neuropathy) and macrovascular events (heart attack, stroke). Life expectancy can approach that of the general population in patients well controlled from early stages.
We owe patients honesty: type 2 diabetes is a chronic disease. There is no cure — not with medications, not with bariatric surgery, not with stem cells. What does exist is remission: a state in which HbA1c stays below 6.5 % without medication for at least three months. It has been documented especially with significant weight loss (more than 10–15 % of body weight) in early stages. Remission does not mean elimination of the disease: it means metabolic control without drugs at that moment. Relapses are possible if weight is regained or an obesogenic pattern returns.
**Reasonable expectations for MSC therapy** in T2D, based on published literature, are: moderate HbA1c reduction (0.5–1.5 points), possible medication dose reduction under medical supervision, improved inflammatory markers and, in some cases, subjective improvement in energy and well-being. Effects are typically observed between months 1 and 3 and tend to consolidate through months 6 and 12. Durability is variable: some patients maintain benefit beyond one year, others consider a follow-up protocol between 12 and 24 months.
A proportion of patients does not respond meaningfully — between 20 and 35 % across different series. This must be discussed before treatment, not after. Predictors of better response are disease duration of less than 10 years, preserved C-peptide, BMI under 35, absence of advanced complications and, above all, commitment to sustained lifestyle change. Cellular therapy without behavioral change yields less. The biological window that an MSC infusion opens is used well or wasted by what the patient does day to day.
What the evidence and our clinical practice support is this: the best diabetes is the one that was prevented, and the second best is the one attended to early by a multidisciplinary team that combines conventional medicine, regenerative tools, clinical nutrition and medical follow-up. We do not promise cures. We do offer an honest plan, based on evidence and designed for the next ten years of your health — not for the next month.
No. Today, in 2026, no therapy cures type 2 diabetes — not metformin, not GLP-1 agonists, not bariatric surgery, not stem cells. Clinical evidence supports that mesenchymal stem cells (MSCs) can improve glycemic control, reduce inflammatory markers and, in selected patients, decrease medication requirements. It is an adjunct tool with moderate results, not a cure. Any clinic that promises otherwise is selling false expectations and should be avoided.
Revisado por Dra. Claudia Labastida · 2026-05-27
The best candidates according to 2026 evidence are adults with T2D of relatively short duration (less than 10–15 years since diagnosis), HbA1c between 7.0 % and 9.5 %, measurable fasting C-peptide (indicating preserved beta-cell reserve), no advanced active complications (end-stage kidney disease, untreated proliferative retinopathy, infected diabetic foot) and documented adherence to conventional treatment. Evaluation includes recent labs and, as appropriate, ophthalmology and cardiology referrals.
Revisado por Dra. Claudia Labastida · 2026-05-27
Any adjustment to your medication must be decided by your treating physician based on your labs and clinical evolution, never unilaterally. In some patients, after MSC therapy and with adherence to lifestyle change, the endocrinologist may consider reducing medication doses. This is not a universal expectation: it depends on your individual response. The goal is not to eliminate drugs for its own sake — it is to achieve the best possible metabolic control with the lowest viable therapeutic burden.
Revisado por Dra. Claudia Labastida · 2026-05-27
Published literature documents sustained effects between 6 and 12 months, with considerable variability between patients. Some maintain improvements in HbA1c, insulin sensitivity and inflammatory markers beyond a year; others experience gradual attenuation. Durability predictors include adherence to lifestyle change, control of comorbidities (blood pressure, lipids, weight) and, in some cases, a follow-up protocol between 12 and 24 months. We discuss honest expectations for your case during the evaluation.
Revisado por Dra. Claudia Labastida · 2026-05-27
The standard route is intravenous infusion, performed at our Cancún clinic under medical supervision. The procedure day, including preparation, monitoring during the infusion and post-observation, usually takes several hours. It does not require hospitalization or general anesthesia. Most patients return to their lodging the same day. The protocol includes structured follow-up sessions at 1, 3, 6 and 12 months with labs to evaluate HbA1c, C-peptide, HOMA-IR and inflammatory markers.
Revisado por Dra. Claudia Labastida · 2026-05-27
In appropriately selected patients and with cellular products processed in COFEPRIS-certified laboratories, the published safety profile is reassuring. Reported adverse effects are generally mild and transient: infusion-related symptoms (low-grade fever, headache, brief fatigue), discomfort at the venipuncture site. Before applying any protocol we conduct a complete medical history, labs, screening for contraindications (active malignancy, active infection, pregnancy, acute metabolic decompensation) and signed detailed informed consent.
Revisado por Dra. Claudia Labastida · 2026-05-27
Three things. First, clinical honesty: we do not promise cures, we present the evidence as it is and we decline cases when they are not candidates. Second, regulatory framework: we operate with a COFEPRIS aviso de funcionamiento, work with certified Mexican laboratories with documented traceability for every cell lot, and our physicians are verifiable. Third, integration: MSCs are combined with IV therapy when applicable, clinical nutrition, an activity plan and coordination with your endocrinologist. We do not sell an isolated procedure — we design a 12-month plan.
Revisado por Dra. Claudia Labastida · 2026-05-27
Yes. Regenerative medicine and IV therapy applications take place at our Cancún clinic, where we operate under a COFEPRIS aviso de funcionamiento. However, the initial evaluation and follow-ups can be partially coordinated by video consultation when feasible. If you are traveling from out of state or abroad, we help with logistics, lodging and scheduling to make the most of your stay. Cancún offers solid medical infrastructure and direct international air access from the United States, Canada and Europe.
Revisado por Dra. Claudia Labastida · 2026-05-27
An honest physician-led review of mesenchymal stem cell therapy for type 2 diabetes: current evidence, mechanisms, candidacy, and regulatory context in Mexico.
A clear, medically grounded introduction to mesenchymal stem cells, where they come from, and why laboratory standards matter.
Your no-hype, science-backed starting point for regenerative treatment in Mexico.
Knee osteoarthritis (gonarthrosis, ICD-10 M17) is the progressive wear of the cartilage that covers the femur, tibia and patella. At Regeneris Therapy we combine current clinical evidence and regenerative medicine to reduce pain, improve mobility and, in selected cases, postpone or avoid total knee replacement.
Learn about Knee OsteoarthritisLumbar disc herniation (ICD-10 M51.2) occurs when the nucleus pulposus of an intervertebral disc displaces through the annulus fibrosus and compresses neighboring nerve structures. At Regeneris Therapy we combine an honest evaluation, recent imaging and mesenchymal stem cell therapy as a middle path between failed conservative care and surgery — for patients who meet clear clinical criteria.
Learn about Lumbar Disc HerniationFibromyalgia is real, medical and deserves an honest approach. At Regeneris Therapy we combine regenerative medicine, IV therapy and an integrative protocol to help you recover energy, sleep and quality of life — always alongside your rheumatologist.
Learn about Fibromyalgia in Cancún: Symptoms, Causes and Regenerative OptionsNext step
Every case of type 2 diabetes is different. Book an evaluation with Dr. Claudia Labastida and the Regeneris team in Cancún: we will review your HbA1c, C-peptide, complete metabolic profile, clinical history and goals. We will give you an honest answer about whether stem cells can complement your treatment and how it would integrate with your endocrinologist. If you are not a candidate, we will say so with the same clarity.